In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on CalciMedica, with a price target of $16.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors related to CalciMedica’s recent developments and future prospects. The company reported its 2Q25 financial results, which, although showing an EPS slightly below expectations, indicated a solid cash position that should support operations into mid-2026. This financial stability is crucial as CalciMedica advances its lead clinical candidate, Auxora, through significant clinical trials.
CalciMedica’s promising discussions with the FDA regarding the Phase 2b CAPRO trial findings and the design for a potential pivotal Phase 3 study in acute pancreatitis (AP) have set a positive regulatory stage. Additionally, the ongoing Phase 2 KOURAGE trial for acute kidney injury (AKI) with Auxora, which has shown promising results in previous studies, further supports the company’s growth potential. These clinical advancements, coupled with the strategic financial management, underpin Pantginis’s optimistic outlook and Buy rating for CalciMedica.
Pantginis covers the Healthcare sector, focusing on stocks such as Krystal Biotech, Capricor Therapeutics, and aTyr Pharma. According to TipRanks, Pantginis has an average return of -14.3% and a 33.67% success rate on recommended stocks.